Aviragen Therapeutics disappoints By: MarketMinute.com Stock News February 14, 2017 at 17:30 PM EST Aviragen Therapeutics Inc. (Nasdaq: AVIR) reported disappointing results from a Phase 2b SPIRITUS trial of vapendavir. The stock price plunged 40 cents to close at $0.68.